Duk-Soo Bae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Duk-Soo Bae has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Won Lee
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
10 shared publications - Byoung-Gie Kim
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
9 shared publications - Tae-Joong Kim
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
8 shared publications - Chel Hun Choi
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
7 shared publications - E. Sun Paik
Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea
4 shared publications - Jae-Weon Kim
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
3 shared publications
Latest Publications
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 5512
Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.
5512 Background: BVAC-C is a B cell- and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, which was well tolerated in HPV positive recurrent cervical carcinoma in phase I study (J Clin Med. 2020 Jan 5;9(1):147). This phase IIa study sought to determine the antitumor activity of BVAC-C. Methods: Twenty-one patients with HPV 16 or 18 positive recurrent cervical cancer who had experienced recurrence after one prior platinum-based combination chemotherapy were enrolled. They were allocated to 3 arms; Arm 1, BVAC-C injection at 0, 4, 8 weeks (1x108 cells/dose); Arm 2, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose); Arm 3, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose) with topotecan at 2, 6, 10, 14 weeks (0.75 mg/m2 for 3 days). Results: The overall response rate was 21% (Arm 1: 29% (2/7), Arm 2: 25% (1/4), Arm 3 : 0 % (0/3)) among the evaluable patients (N = 14), and the median duration of response was 18 months (range, 9 – 26 months). The disease control rate was 43% (Arm 1: 29% (2/7), Arm 2: 50% (2/4), Arm 3 : 67 % (2/3)) and the median duration of stable disease were 12 months (range, 6 - 26 months). The median progression-free survival in all patients was 4 months (95% CI, 2 to Infinite months). Immune responses of patients after vaccination were shown to be correlated with clinical responses of them. Consistent with Phase I study, all evaluated patients showed not only inflammatory cytokine responses (IFN-γ or TNF-α), which might be mediated by the activation of natural killer cells and natural killer T cells, but also potent E6/E7-specific T cell responses upon vaccinations. Conclusions: BVAC-C demonstrated a durable antitumor activity with an immune response in HPV 16- or 18-positive recurrent cervical carcinoma patients who failed 1st line platinum based chemotherapy. Clinical trial information: NCT02866006.
- 20 May 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (15_suppl) , 5512
Phase IIa study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma.
5512 Background: BVAC-C is a B cell- and monocyte-based immunotherapeutic vaccine transfected with recombinant HPV E6/E7, which was well tolerated in HPV positive recurrent cervical carcinoma in phase I study (J Clin Med. 2020 Jan 5;9(1):147). This phase IIa study sought to determine the antitumor activity of BVAC-C. Methods: Twenty-one patients with HPV 16 or 18 positive recurrent cervical cancer who had experienced recurrence after one prior platinum-based combination chemotherapy were enrolled. They were allocated to 3 arms; Arm 1, BVAC-C injection at 0, 4, 8 weeks (1x108 cells/dose); Arm 2, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose); Arm 3, BVAC-C injection at 0, 4, 8, 12 weeks (5x107 cells/dose) with topotecan at 2, 6, 10, 14 weeks (0.75 mg/m2 for 3 days). Results: The overall response rate was 21% (Arm 1: 29% (2/7), Arm 2: 25% (1/4), Arm 3 : 0 % (0/3)) among the evaluable patients (N = 14), and the median duration of response was 18 months (range, 9 – 26 months). The disease control rate was 43% (Arm 1: 29% (2/7), Arm 2: 50% (2/4), Arm 3 : 67 % (2/3)) and the median duration of stable disease were 12 months (range, 6 - 26 months). The median progression-free survival in all patients was 4 months (95% CI, 2 to Infinite months). Immune responses of patients after vaccination were shown to be correlated with clinical responses of them. Consistent with Phase I study, all evaluated patients showed not only inflammatory cytokine responses (IFN-γ or TNF-α), which might be mediated by the activation of natural killer cells and natural killer T cells, but also potent E6/E7-specific T cell responses upon vaccinations. Conclusions: BVAC-C demonstrated a durable antitumor activity with an immune response in HPV 16- or 18-positive recurrent cervical carcinoma patients who failed 1st line platinum based chemotherapy. Clinical trial information: NCT02866006.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (5)
Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features
Kim N, et al. J Gynecol Oncol. 2021 May;32:e72. https://doi.org/10.3802/jgo.2021.32.e72
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (5)
Open AccessSignificance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features
Kim N, et al. J Gynecol Oncol. 2021 May;32:e72. https://doi.org/10.3802/jgo.2021.32.e72
- Open Access
- 1 February 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (2) , 473-481
In Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model
- 1 February 2020
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 27 (2) , 473-481
Open AccessIn Vivo Comparison of MONOFIX, A Novel Barbed Suture with a Triangular Stopper, with Pre-existing Products in a Porcine Model
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e65
Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods
Paik ES, et al. J Gynecol Oncol. 2018 Aug;30:e65. https://doi.org/10.3802/jgo.2019.30.e65
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (4) , e65
Open AccessPrediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods
Paik ES, et al. J Gynecol Oncol. 2018 Aug;30:e65. https://doi.org/10.3802/jgo.2019.30.e65
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e47
Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study
Kim MK, et al. J Gynecol Oncol. 2018 Aug;30:e47. https://doi.org/10.3802/jgo.2019.30.e47
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (2) , e47
Open AccessSix months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study
Kim MK, et al. J Gynecol Oncol. 2018 Aug;30:e47. https://doi.org/10.3802/jgo.2019.30.e47
- Open Access
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e11
Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J, et al. J Gynecol Oncol. 2018 Oct;30(1):e11. https://doi.org/10.3802/jgo.2019.30.e11
- 1 January 2019
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 30 (1) , e11
Open AccessOptimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?
Kim J, et al. J Gynecol Oncol. 2018 Oct;30(1):e11. https://doi.org/10.3802/jgo.2019.30.e11
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (4) , e56
Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement
Suh DH, et al. J Gynecol Oncol. 2018 Mar;29(4):e56. https://doi.org/10.3802/jgo.2018.29.e56
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (4) , e56
Open AccessPractice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement
Suh DH, et al. J Gynecol Oncol. 2018 Mar;29(4):e56. https://doi.org/10.3802/jgo.2018.29.e56
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (2) , e18
Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
Paik ES, et al. J Gynecol Oncol. 2017 Dec;29:e18. https://doi.org/10.3802/jgo.2018.29.e18
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (2) , e18
Open AccessClinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis
Paik ES, et al. J Gynecol Oncol. 2017 Dec;29:e18. https://doi.org/10.3802/jgo.2018.29.e18
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (1) , e13
Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
Paik ES, et al. J Gynecol Oncol. 2017 Sep;29(1):e13. https://doi.org/10.3802/jgo.2018.29.e13
- 1 January 2018
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 29 (1) , e13
Open AccessPrognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer
Paik ES, et al. J Gynecol Oncol. 2017 Sep;29(1):e13. https://doi.org/10.3802/jgo.2018.29.e13
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1969-1975
Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K)
Nam SH, et al. J Korean Med Sci. 2016 Dec;31(12):1969-1975. https://doi.org/10.3346/jkms.2016.31.12.1969
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1969-1975
Open AccessDevelopment and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K)
Nam SH, et al. J Korean Med Sci. 2016 Dec;31(12):1969-1975. https://doi.org/10.3346/jkms.2016.31.12.1969